我们使用cookie改善您的浏览体验并提供有意义的内容。请阅读我们的cookie协议
收藏我们 在线订购
     

机构用户解决方案

产品选择指南

技术服务信息

当前位置:首页> 产品选择指南 > 干细胞研究相关制品 > 细胞 (Cell) > Human Stem Cell Derived Cardiomyocytes
Human Stem Cell Derived Cardiomyocytes
品牌 Code No. 产品名称 包装量 价格(元) 说明书 数量
Cellartis Y10060 Cellartis® Pure hES-CM 1 Kit ¥14,611
Cellartis Y10075 Cellartis® Cardiomyocytes (from ChiSPC22) Kit 1 Kit ¥14,611
无标题文档
人ES细胞来源心肌细胞
(Cardiomyocytes Derived from Human Embryonic Pluripotent Stem Cells)
Cellartis Pure Cardiomyocytes (from SA121) 是由基因工程技术改良的人ES细胞株(SA121-cTnT)分化而来的心肌细胞,纯度高(约 90%),可进行维持培养。
 
人iPS细胞来源心肌细胞
(Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells)
Cellartis Cardiomyocytes是从人iPS细胞(细胞株ChiPSC22)分化来的高度同质、均一的心肌细胞。本产品与人心肌细胞高度相似,是由iPS细胞分化来的表现出自发搏动能力的心肌细胞。本产品在科研界和药物研发公司广泛采用。
 
■ 产品特点
· Electrophysiological profile highly resembling adult human primary cardiomyocytes
· Respond as expected to cardiac stimuli
· Genetically unmodified cell line derived without selection(Y10075)
· Cells are provided with basal media for thawing and culture
 
■ 产品应用
· Safety pharmacology
· Cardiotoxicity testing
· Discovery of novel cardiac drug targets
· Phenotypic screening
· High-content analysis (HCA)
 
Code No. Product Size
Y10060 Cellartis® Pure Cardiomyocytes (from SA121) Kit 1 Kit
Y10062 Cellartis® CM Thawing Base 32 mL
Y10063 Cellartis® CM Culture Base 90 mL
Y10075 Cellartis® Cardiomyocytes (from ChiPSC22) Kit 1 Kit
 
■ 产品详情请点击:
 
[ 确定Cellartis心肌细胞标志物的表达 ]:
 
[Cellartis 心肌细胞的动作电位]:
 
参考文献:
1. Synnergren J et al.Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells.Stem Cells 2008 Jul; 26(7): 1831-1840.
2. Jonsson MK et al. Quantified Proarrhythmic Potential of Selected Human Embryonic Stem Cell-derived Cardiomyocytes.Stem Cell Res. 2010 May; 4(3): 189-200.
3. Synnergren J et al. Expression of microRNAs and their target mRNAs in human stem cell derived cardiomyocyte clusters and in heart tissue. Physiol. Genomics 2011 May 1; 43(10): 581-594.
4. Nalos L et al. Comparison of the IKr blockers, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br. J. Pharmacol. 2012 Jan; 165(2): 467-478.
5. Synnergren J et al. Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiol. Genomics 2012 Feb 27; 44(4): 245-258.
6. Yamazaki K et al. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicol. In Vitro. 2012 Mar; 26(2): 335-342.
7. Jonsson MK et al. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J. Mol. Cell Cardiol. 2012 May; 52(5): 998-1008.
8. hnke et al. A novel 3D label-free monitoring system of hES-derived cardiomyocyte clusters: a step forward to in vitro cardiotoxicity testing. PLoS One 2013 Jul ;8(7).
9. Yamazaki et al. Beat-to-Beat Variability in Field Potential Duration in Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters for Assessment of Arrhythmogenic Risk, and a Case Study of Its Application. Pharmacol. & Pharm, 2014, 5, 117-128.